GW Pharma to commence epilepsy drug trial in 2H


The FDA gives GW Pharmaceuticals (GWPH) the green light to commence its Phase 2/3 clinical trial for Epidiolex, its orphan drug-designated  treatment for Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. The trial should start in 2H 2014.

The first part of the study will dose 30 patients over a three-week time frame to evaluate the drug's pharmacokinetics and clarify the appropriate dosing parameters. The second part will be a placebo-controlled evaluation of Epidiolex for safety and efficacy in 80 patients over three months. The Phase 3 trial should commence in Q1 2015.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs